ArticleHealth science reports2023
The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): A systematic review and meta-analysis protocol.
Article in Health science reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of pharmacist interventions in chronic kidney disease: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Pooled it
- Knowledge, attitudes, and practices of pharmacists towards chronic kidney disease in Rawalpindi and Islamabad, Pakistan: a cross-sectional study.BMC medical education · 2026Article
- Mind the gap in kidney care: translating what we know into what we do.Kidney research and clinical practice · 2025Article
- Mind the gap in kidney care: Translating what we know into what we do.Nephrology (Carlton, Vic.) · 2025Article
- Mind the gap in kidney care: translating what we know into what we do.Clinical and experimental nephrology · 2024Review
- Care of Adults with Advanced Chronic Kidney Disease.Journal of clinical medicine · 2024Review
- Mind the Gap in Kidney Care: Translating What We Know Into What We Do.American journal of hypertension · 2024Article
- Mind the Gap in Kidney Care: Translating What We Know into What We Do.Kidney international reports · 2024Article
- Mind the gap in kidney care: Translating what we know into what we do.Journal of family medicine and primary care · 2024Article
- Mind the gap in kidney care: translating what we know into what we do.Jornal brasileiro de nefrologia · 2024Article
- Mind the Gap in Kidney Care: Translating What We Know Into What We do.Canadian journal of kidney health and disease · 2024Article
- Curvilinear association between Framingham Steatosis Index and chronic kidney disease: a nationwide cross-sectional study.Frontiers in medicine · 2024Article
- Mind the Gap in Kidney Care: Translating What We Know into What We Do.Blood purification · 2024Article
- The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): A systematic review and meta-analysis protocol.Health science reports · 2023Article
- Mind the Gap in Kidney Care: Translating What We Know into What We Do.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Chronic kidney disease (CKD) is a progressive condition that results in a decline in kidney function over time. There are several conditions that increase the likelihood of developing CKD, particularly diabetes and hypertension. CKD increases the risk of mortality and has a detrimental impact on quality of life (QoL). Strategies for managing CKD include controlling cardiovascular risk factors and treating complications of CKD. There is an ever-increasing role of pharmacists in managing CKD, from the optimization of risk factors to patient education. However, currently, there is a lack of data on the effect pharmacist-led interventions have on the clinical, economic, and humanistic outcomes. Methods: This protocol, in adherence to PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) standards, describes a prospective systematic review and meta-analysis of randomized controlled trials, where any intervention led by a pharmacist in CKD is used. Comparison groups will consist of usual care or non-pharmacist-led interventions. Literature searches will be conducted in the following databases: MEDLINE, Scopus, and Web of Science. Data pertaining to clinical (e.g., mortality), economic (e.g., healthcare-associated costs), and humanistic (e.g., QoL) outcomes will be extracted. Risk of bias will be assessed using the United States National Heart Lung and Blood Institute quality assessment tool for controlled intervention studies. A meta-analysis will be conducted to synthesize appropriate comparable outcomes. Results: The findings of this review will be published in a peer-reviewed journal, where the results will be presented in lay language with appropriate infographics online and via social media. Conclusion: The findings of this review can identify gaps in the literature concerning optimizing pharmacist-led interventions in improving outcomes. In addition, this review will establish the importance of pharmacists in managing CKD patients, and whether this may result in their increased incorporation in multidisciplinary teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.